← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
7 Hills Pharma, Llc
Houston, TX
$13,892,074
Total funding
10
Grants
Funding over time
peak $3M · FY2016–24$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,892,074 · 10
By mechanism
R44$8,875,135 · 4
R42$3,866,297 · 2
R41$852,918 · 3
R43$297,724 · 1
Investigators at 7 Hills Pharma, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors$1,015,591
R44 · FY2021 · CA
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$1,001,898
R42 · FY2019 · CA
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$999,501
R42 · FY2018 · CA
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$999,300
R44 · FY2022 · AI
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors$999,200
R44 · FY2023 · CA
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors$999,200
R44 · FY2024 · CA
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$997,867
R44 · FY2023 · AI
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$997,867
R44 · FY2024 · AI
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors$984,409
R44 · FY2020 · CA
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$953,477
R44 · FY2024 · AI
A small molecule integrin activator to enhance cord blood transplant$935,957
R42 · FY2020 · HL
A small molecule integrin activator to enhance cord blood transplant$928,941
R42 · FY2021 · HL
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$928,224
R44 · FY2023 · AI
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$313,705
R41 · FY2016 · CA
Integrin Activation to Augment SARS-CoV-2 Vaccination$297,724
R43 · FY2021 · AI
A small molecule integrin activator to enhance cord blood transplant$295,931
R41 · FY2016 · HL
Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies$243,282
R41 · FY2019 · AI